Olaparib, rucaparib, niraparib, and talazoparib targeting PARP1/2 have been approved by the United States Food and Drug Administration (FDA) for the treatment of breast or ovarian cancer in patients harboring HR mutations that induce synthetic lethality in the BRCA1 or BRCA2 gene. This evidence concerns the gene BRCA1 and ovarian carcinoma.